{"url_path":"/sec/avbp/8-k/2026-06-22/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1868279/0001104659-26-076352-index.html","accession_number":"0001104659-26-076352","cik":"0001868279","ticker":"AVBP","issuer_name":"ArriVent BioPharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1868279/0001104659-26-076352-index.html","primary_entity_key":"0001868279","primary_entity_name":"ArriVent BioPharma, Inc."},"word_count":353,"has_tables":true,"body_markdown":"**Item 5.07 Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn June 18, 2026, ArriVent\nBioPharma, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) via live audio\nwebcast on the Internet. Of the 46,368,442 shares of common stock, par value $0.0001 per share, issued and outstanding and eligible to\nvote as of the record date of April 21, 2026, a quorum of 33,418,793 shares, or 72.07% of the eligible shares, was present at the meeting\nor represented by proxy.\n\n \n\nAt the Annual Meeting,\nthe stockholders: (1) elected each of James Healy, M.D., Ph.D., John Hohneker, M.D., and Stuart Lutzker, M.D., Ph.D. to the Company’s\nboard of directors as a Class II director for a term of three years to serve until the 2029 annual meeting of stockholders and until his\nor her successor is duly elected and qualified or until his or her earlier death, resignation, or removal (“Election of Directors”);\nand (2) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for\nthe fiscal year ending December 31, 2026 (“Auditor Ratification”). A more complete description of each of these matters is\nset forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April\n28, 2026.\n\n \n\nThe number of votes cast\nin favor or against or withheld by the stockholders and, where applicable, the number of abstentions and the number of broker non-votes\non each of the foregoing matters are set forth below.\n\n \n\n1. Election of Directors\n\n \n\n**Nominee**\n \n**Shares Voted For**\n \n\n**Shares Voted to Withhold**\n\n**Authority**\n\n \n**Broker Non-votes**\n\nJames Healy, M.D., Ph.D.\n \n18,058,285\n \n11,527,650\n \n3,832,858\n\nJohn Hohneker, M.D.\n \n28,043,164\n \n1,542,771\n \n3,832,858\n\nStuart Lutzker, M.D., Ph.D.\n \n29,495,923\n \n90,012\n \n3,832,858\n\n \n\n2. Auditor Ratification\n\n \n\n**Shares Voted For**\n \n**Shares Voted Against**\n \n**Shares Abstaining**\n \n**Broker Non-votes**\n\n33,411,773\n \n829\n \n6,191\n \n0\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n**ARRIVENT BIOPHARMA, INC.**\n\n \n \n \n\n \nBy:\n/s/ Winston Kung\n\n \n \nWinston Kung\n\n \n \nChief Financial Officer and Treasurer\n\n \n\nDate: June 22, 2026"}